These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12228889)

  • 1. Competing designs for phase I clinical trials: a review.
    Rosenberger WF; Haines LM
    Stat Med; 2002 Sep; 21(18):2757-70. PubMed ID: 12228889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
    Mander AP; Sweeting MJ
    Stat Med; 2015 Apr; 34(8):1261-76. PubMed ID: 25630638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-and-down designs for phase I clinical trials.
    Liu S; Cai C; Ning J
    Contemp Clin Trials; 2013 Sep; 36(1):218-27. PubMed ID: 23856381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
    Rossoni C; Bardet A; Geoerger B; Paoletti X
    Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continual reassessment and related designs in dose-finding studies.
    Iasonos A; O'Quigley J
    Stat Med; 2011 Jul; 30(17):2057-61. PubMed ID: 21351292
    [No Abstract]   [Full Text] [Related]  

  • 10. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A web application for evaluating Phase I methods using a non-parametric optimal benchmark.
    Wages NA; Varhegyi N
    Clin Trials; 2017 Oct; 14(5):553-557. PubMed ID: 28649874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
    Mozgunov P; Jaki T; Paoletti X
    J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-dimensional biased coin design for dual-agent dose-finding trials.
    Sun Z; Braun TM
    Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optimization algorithm for designing phase I cancer clinical trials.
    Jiang H; Liu Y; Su Z
    Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. Wages.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):23-6. PubMed ID: 25492617
    [No Abstract]   [Full Text] [Related]  

  • 17. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.
    Wages NA
    Stat Med; 2015 Jan; 34(1):18-22. PubMed ID: 25492616
    [No Abstract]   [Full Text] [Related]  

  • 20. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. Zohar.
    Yin G; Lin R
    Stat Med; 2015 Jan; 34(1):13-7. PubMed ID: 25492615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.